OcuSciences Announces Publication Showing OcuMet Beacon Retinal Imager May Detect Glaucoma Earlier Than Current Standard Measures and Be Useful in Assessing Disease Severity

ANN ARBOR, Mich.--(BUSINESS WIRE)--OcuSciences, Inc., a clinical-stage biotechnology company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the online publication of its initial glaucoma study. The findings illustrate a possible paradigm shift in the way in which glaucoma is currently diagnosed and monitored. The study was led by Richard Rosen, MD, Professor of Ophthalmology, and Robert Ritch, MD, Professor of Ophthalmology and Direct

Full Story →